Mesalamine and Foot deformity - a phase IV clinical study of FDA data

Summary:

Foot deformity is reported as a side effect among people who take Mesalamine (mesalamine), especially for people who are female, 40-49 old, also take Prednisone, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Foot deformity when taking Mesalamine. It is created by eHealthMe based on reports of 27,767 people who have side effects when taking Mesalamine from the FDA, and is updated regularly.

What is Mesalamine?

Mesalamine has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 28,053 Mesalamine users. Check the latest studies of Mesalamine.

What is Foot deformity?

Foot deformity (functional disability of foot) is found to be associated with 913 drugs and 705 conditions by eHealthMe. Check the latest studies of Foot deformity.

On Jul, 09, 2026

27,767 people reported to have side effects when taking Mesalamine.
Among them, 47 people (0.17%) have Foot deformity.

Among these 47 people:

What is the gender of people who have Foot deformity when taking Mesalamine? *

female: 86.49 %
male: 13.51 %

What is the age of people who have Foot deformity when taking Mesalamine? *

What are other drugs people take besides Mesalamine? *

Prednisone: 41 people, 87.23%
Azathioprine: 40 people, 85.11%
Desoximetasone: 38 people, 80.85%
Acetaminophen: 36 people, 76.60%
Diclofenac Potassium: 36 people, 76.60%
Diclofenac Sodium: 35 people, 74.47%
Hydrocortisone Acetate: 35 people, 74.47%
Cimzia: 34 people, 72.34%
Otezla: 33 people, 70.21%
Celecoxib: 33 people, 70.21%

What are other side effects people have besides Foot deformity? *

Exostosis (formation of new bone on the surface of a bone): 38 people, 80.85%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 38 people, 80.85%
Otitis (ear infection): 37 people, 78.72%
Diarrhea: 37 people, 78.72%
Laryngitis (inflammation of the larynx): 36 people, 76.60%
Indigestion: 35 people, 74.47%
Fatigue (feeling of tiredness): 35 people, 74.47%
General Physical Health Deterioration (weak health status): 35 people, 74.47%
Hair Loss: 35 people, 74.47%
High Blood Cholesterol: 35 people, 74.47%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 30 people, 63.83%
Psoriasis (immune-mediated disease that affects the skin): 25 people, 53.19%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 23 people, 48.94%
Joint Pain: 12 people, 25.53%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 3 people, 6.38%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 6.38%
Stress And Anxiety: 2 people, 4.26%
Abdominal Discomfort: 2 people, 4.26%
Sleep Disorder: 1 person, 2.13%
Osteomyelitis (infection of bone): 1 person, 2.13%

* Approximation only. Some reports may have incomplete information.

Do you take Mesalamine and have Foot deformity?

- Check whether Foot deformity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mesalamine:

Mesalamine (28,053 reports)

Foot deformity treatments and more:

Foot deformity (14,397 reports)

Browse all side effects of Mesalamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Foot deformity:

Foot deformity (913 drugs)

Browse all the conditions that are associated with Foot deformity:

Foot deformity (705 conditions)

Related publications that referenced our studies

Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .
Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on mesalamine (the active ingredients of Mesalamine) and Mesalamine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.